NCT04624971

Brief Summary

The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

November 6, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 12, 2020

Completed
Last Updated

November 12, 2020

Status Verified

November 1, 2020

Enrollment Period

Same day

First QC Date

November 6, 2020

Last Update Submit

November 6, 2020

Conditions

Diffuse Large B Cell Lymphoma

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    5-year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with clinical information available

You may qualify if:

  • histologically confirmed diagnosis of CD20+ DLBCL

You may not qualify if:

  • primary central nervous system lymphoma
  • "double-hit" lymphoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Guangdong General Hospital

Guangzhou, Guangdong, 510000, China

Location

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,

Guangzhou, 51000, China

Location

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,

Guangzhou, 51000, China

Location

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Condition Hierarchy (Ancestors)

Lymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Qingqing Cai, MD

CONTACT

0086-20-87342823caiqq@sysucc.org.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief physician

Study Record Dates

First Submitted

November 6, 2020

First Posted

November 12, 2020

Study Start

November 1, 2020

Primary Completion

November 1, 2020

Study Completion

November 1, 2020

Last Updated

November 12, 2020

Record last verified: 2020-11

Locations

CN(3)